Piramal Pharma Ltd (NSE: PPLPHARMA) and RUBICON RESEARCH LIMITED (NSE: RUBICON) are both listed in the Pharmaceuticals industry. Piramal Pharma has a market capitalisation of ₹31,892 Cr and RUBICON RESEARCH ₹27,601 Cr, as of 9 Nov 2026. Return on equity is -4.00% for Piramal Pharma and 19.14% for RUBICON RESEARCH. Over one year, Piramal Pharma's share price is up 21.7% and RUBICON RESEARCH's is up 186.9%.
| Metric | Piramal Pharma | RUBICON RESEARCH |
|---|---|---|
| NSE Symbol | PPLPHARMA | RUBICON |
| BSE Code | 543635 | 544578 |
| Share Price | ₹245.30 | ₹1,773.60 |
| Market Cap | ₹31,892 Cr | ₹27,601 Cr |
| P/E Ratio | Not meaningful (loss) | 108.9 |
| Return on Equity | -4.00% | 19.14% |
| Return on Assets | 0.36% | 11.74% |
| Dividend Yield | 0.00% | 0.09% |
| Beta (1Y) | 0.31 | 0.13 |
| 1-Year Price Change | +21.7% | +186.9% |
| 3-Month Price Change | +14.8% | +11.1% |
| 52-Week Range | ₹132.30 – ₹250.40 | ₹615.20 – ₹1,899.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹2,617 Cr | ₹576 Cr |
| Quarterly Net Profit | ₹5 Cr | ₹90 Cr |
| Net Margin | 0.2% | 15.7% |
| EPS (Basic, Quarter) | ₹0.04 | ₹5.47 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generi…
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabol…
Piramal Pharma has a market capitalisation of ₹31,892 Cr, against ₹27,601 Cr for RUBICON RESEARCH as of 9 Nov 2026, about 1.2 times the size by market cap.
Piramal Pharma has a return on equity of -4.00% and RUBICON RESEARCH 19.14%.
Piramal Pharma's share price is up 21.7% over one year and RUBICON RESEARCH's is up 186.9%.
Piramal Pharma reported revenue of ₹2,617 Cr and net profit of ₹5 Cr for Q2 FY27. RUBICON RESEARCH reported revenue of ₹576 Cr and net profit of ₹90 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.